Introduction
CD45 (PTPRC, leukocyte common antigen, B220, T200) was one of the first signaling molecules identified on leukocytes. [1] [2] [3] [4] [5] [6] [7] Humans with certain mutations in CD45 or mice that are deficient in CD45 develop a servecombined immunodeficiency phenotype, systemic lupus erythematosus and many other diseases. [8] [9] [10] [11] [12] [13] CD45 is expressed on all nucleated hematopoetic cells and is therefore widely used as a pan-leukocyte marker molecule. CD45
is a prototypic transmembrane protein tyrosine phosphatase (PTP) and it is generally accepted today that it sets the threshold of positive and negative signaling events in leukocytes. [12] [13] [14] [15] Through dephosphorylation and activation of the src-family kinases Lck, Fyn and Lyn, CD45 is a positive regulator for signaling via the T cell and B cell receptors, respectively. [16] [17] [18] On the other hand, through dephosphorylation of JAK, CD45 has been shown to negatively regulate cytokine receptor signaling and promotes viral infections. 19 In addition CD45 is involved in regulating development, adhesion and apoptosis in leukocytes. 12, 13 CD45 is an abundant and large cell surface glycoprotein of 180-220 kDa, comprising up to 10 % of the leukocyte surface area. 20 It exists in several isoforms generated by alternative splicing of exons 4,5 and 6, each with varying sized extracellular domains. 13 These extracellular domains are poorly conserved among species and heavily glycosylated. In contrast, the 707 aa large cytoplasmic part of CD45 is conserved and contains two tandemly duplicated protein tyrosine phosphatase homology (PTP) domains, D1 and D2. Only D1 has phosphatase activity. The function of D2 is unclear and may contribute to stabilize D1. [21] [22] [23] [24] [25] 3 only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From A growing number of PTPs is now known to undergo post-translational proteolytic processing. [26] [27] [28] [29] [30] For instance, the CD45-related receptor-type PTP (RPTP) LAR has been reported to be cleaved by the presenilin/γ-secretase complex. 27 Cleavage of the intracellular parts of type-I cell surface receptors by presenilin/γ-secretase is typically executed after the receptors have undergone ecto-domain shedding. 26, 27, 29, 30 Interestingly, proteolysis by the presenilin/γ-secretase is not only a simple degradation process but frequently generates fragments of cell surface receptors with novel biological functions. 29, 30 Whether CD45 is proteolytically processed in leukocytes has not been investigated yet.
Therefore we used a novel monoclonal antibody (mAb) 8-301, which is directed against the cytoplasmic tail of CD45, as a tool to analyze potential CD45 cleavage fragments in leukocytes and test their immunological function.
We demonstrate in this study that the intracellular PTP-domain of CD45 (ct-CD45) is proteolytically cleaved and released upon phagocyte activation by fungi or PMA and functions as an inhibitor of T cell activation.
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Materials and methods
Media, reagents, and chemicals. Cells were maintained in RPMI 1640 (Gibco Ltd., Paisley, Scotland), supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and 10 % FCS (Sigma-Aldrich, St. Louis, MO). Recombinant human GM-CSF and IL-4 were kindly provided by Novartis Research Institute (Vienna, Austria). LPS from Eschericha coli (serotype 0127-B8; used at 1 μg/mL), zymosan A (100 μg/mL), β-glucan from Saccharomyces cerivisiae (100 μg/mL), peptidoglycan from Staphylococcus aureus (100 μg/mL), laminarin from Laminaria digitata (5 mg/mL), Poly I:C (20 μg/mL), PMA (100 nM), cycloheximide (2 and 10 μg/mL), propidium iodide, AEBSF (200 μM), aprotinin (20 μg/mL) and E64d (100 μM) were from SigmaAldrich. Pam3CSK4 (10 μg/mL) and CpG (ODN2006, used at 0,5 mM) were from Invivogen (San Diego, CA). Annexin V-FITC was from Caltag (Burlingame, CA). Candida albicans (ATCC 44374) was obtained from ATCC (Rockville, Maryland, USA).
Apocynin (used at 1 mM), piceatannol (50 μM), EGTA (5 mM), calpeptin (100 μM), MG-132 (100 μM), pepstatin (2 μM), PTPase CD45 inhibitor (1 mM) and γ-secretase inhibitor X (5 μM) were from Calbiochem (Darmstadt, Germany). IL-10 was purchased from R&D Systems Inc. Antibodies and fusion-proteins. MAb 8-301 (IgG1) was generated in our laboratory by immunizing BALB/c mice with human T cell lysates. Murine negative control Ab VIAP (calf intestine alkaline phosphatase specific) was also generated in our laboratory. Anti-CD45 (MEM-28) was from Abcam We analyzed the protein sequence of the potential fragment by massspectrometry. The data presented in supplementary figure 1 shows that we could identify 11 peptides, which all aligned to the intracellular part of CD45.
Furthermore we found that upon 3 h stimulation the 95 kDa protein is located in the cytoplasmic and not in the membrane fraction ( Figure 2B ). The ratio of intact versus cleaved CD45 molecules was determined by densitometric analysis and we found that 29 ± 6% and 9 ± 4% of the CD45 molecules are For
CD45
. We also tested whether ct-CD45 is produced by the induction of cell death. Inducers of cell death like cycloheximide or staurosporine or freeze/thaw cycles did not lead to ct-CD45 generation (data not shown). (CD11b/CD18), Dectin-1, the major β-glucan receptor on myeloid cells, was recently discovered to be an important player in controlling fungal infection. [38] [39] [40] [41] As zymosan is mainly composed of β-glucan 42 and the TLR2 stimuli Pam3Cys did not induce ct-CD45 ( Figure 3A) , we tested whether ct-CD45
can be produced upon ligation of Dectin-1. Therefore we used a particulate β-glucan preparation from S. cerivisiae, which induced a slight ct-CD45 band ( Figure 3E ). Furthermore we investigated whether induction of ct-CD45 by zymosan can be blocked by the soluble β-glucan laminarin from Laminaria digitata, which was shown to block activation by zymosan via Dectin-1. 38, 40, 43 We found that laminarin strongly inhibited zymosan-induced production of ct-CD45 ( Figure 3E ). Ligation of Dectin-1 leads to activation of Syk tyrosine kinase, which is important for zymosan-induced respiratory burst in phagocytes. 44 We found that the generation of ct-CD45 by zymosan but not by PMA was blocked by the Syk kinase inhibitor piceatannol ( Figure 3F ).
Thus, we concluded that ligation of Dectin-1 is critically involved in the induction of ct-CD45 by zymosan. As both, zymosan and PMA are able to induce an oxidative burst in phagocytes (data not shown) we tested whether oxidative burst formation is involved in ct-CD45 generation. Remarkably, apocynin, which blocks the oxidative burst by specifically inhibiting the assembly of the functional NADPH-oxidase complex, was indeed able to block ct-CD45 production by zymosan as well as by PMA ( Figure 3F ).
Ct-CD45 is generated by proteolytic cleavage. As we could detect ct-CD45 in the cytoplasmic fraction ( Figure 2B ) and found a diminished reactivity of MEM-28 upon stimulation suggesting the release of the CD45 ectodomain ( Figure 3B ) we hypothesized that CD45 could be processed by a mechanism including several cleavage steps. However in addition we also examined whether ct-CD45 is a so far unknown translational variant. We tested whether inhibition of de novo protein synthesis with cycloheximide could inhibit ct-CD45 generation. 45 However, as shown in Figure 4A , ct-CD45 was expressed during monocyte stimulation with zymosan or PMA in the presence of cycloheximide, which completely prevented the induction of typical monocyte activation markers such as sialoadhesin (CD169) analyzed in parallel (data not shown).
As ct-CD45 is not de novo synthesized we further examined our hypothesis that ct-CD45 is generated by proteolysis from intact CD45 molecules. To test which protease could be involved in ct-CD45 cleavage we 46, 47 We indeed found that the number of annexin and propidium iodide positive cells increased upon PMA or zymosan treatment ( Figure 5A and data not shown). We hypothesized that the observed decrease of ct-CD45 in cell lysates ( Figure 2A ) might be due to further degradation or release of ct-CD45 from dying cells into the supernatant. Results presented in Figure 5B demonstrate that ct-CD45 was indeed detectable in the supernatant of activated monocytes after 4 to 16h. We measured by densitometric analysis of Western Blots that 1 x 10 6 monocytes release 859 ± 496 pg and 180 ± 81 pg of ct-CD45 upon stimulation with PMA and zymosan, respectively (n=3 donors). Granulocytes (1 x 10 6 ) release even slightly more ct-CD45 (1.181 ± 308 pg, n=3 donors) upon stimulation with PMA. The appearance of ct-CD45 in the supernatant of phagocytes correlated with lactate dehydrogenase release, a cytoplasmic protein typically released upon membrane leakage due to cell death ( Figure 5C ). We found that ct-CD45 isolated from the supernatant of phagocytes retained its phosphatases activity ( Figure 5D ).
Taken together, we concluded that ct-CD45 after stimulation-induced cleavage seems to be released from phagocytes mainly due to cell death. Figure 6A ) 48 , indicating that the PTPase activity of ct-CD45 is not essential for binding to T cells.
Ct-CD45 inhibits T cell proliferation.
In order to examine whether binding of ct-CD45 to T cells has immuneregulatory consequences we added ct-CD45 proteins to an MLR. We observed that ct-CD45 reduced T cell proliferation induced by DC. This inhibitory effect of ct-CD45 was comparable to that found with IL-10, the classical inhibitory factor for T cells, and was not seen with recombinant S100A4 protein used for control ( Figure 6C ). We also observed this inhibitory function when we stimulated T cells with plate bound anti-CD3 in the presence of immobilized ct-CD45-Ig fusion proteins ( Figure 6D ). Inhibition of proliferation was independent of the phosphatase domain of CD45 as a phosphatase-dead D1-Ig protein induced the same effect as active protein.
The D2-Ig showed a weaker inhibitory effect than D1-Ig especially at a lower dose. Figure 6E shows that inhibition of T cell proliferation by different ct-CD45-Ig proteins was not due to cell death. Ct-CD45 thus represents a novel immune-regulatory factor for human T cells.
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Discussion
In this study we demonstrate an alternative function for CD45. We observed that cytoplasmic tails of CD45 molecules are cleaved and released upon activation of phagocytes and act as cytokine-like factors with negative immune-regulatory function on T cells. Thereby, ct-CD45 can act as an intercellular regulator between the innate and the adaptive immune system. We have discovered this phenomenon when we studied the existence of post-translationally processed CD45 molecules with a mAb directed against the cytoplasmic part. Ct-CD45 was found in monocytes and neutrophil granulocytes but not in leukocytes or DC upon activation with PMA, the fungal cell wall component zymosan or C.albicans. Ct-CD45 was not detectable after induction of cell death. Together with the finding that ct-CD45 molecules are also generated in the presence of cycloheximide, which blocks ribosomal translation, the rapid appearance of ct-CD45 within 1 h suggested that it might not be derived from newly synthesized, alternative splice variants of CD45. Alternative splicing of the extracellular part of CD45 is wellinvestigated and responsible for the generation of CD45 isoforms but has not been reported to occur within the conserved intracellular PTP-domains. 13, 15, 45 We could show that cleavage of the cytoplasmic tail from intact CD45 molecules by proteases is responsible for the accumulation of ct-CD45.
Proteolysis of other transmembrane and non-receptor type PTPs has been reported before in several studies. [49] [50] [51] Cleavage of the intracellular domains of type-I cell surface receptors is typically executed by the presinilin/γ-secretase complex after the receptors, including some RPTPs, have undergone ecto-domain shedding. 26, 27, 29, 30 For instance, the CD45-related 20 only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From receptor-type PTP LAR has been reported to be cleaved by the γ-secretase pathway. 27 The extracellular part of CD45 has been reported to be cleaved by trypsin digestion. 52 Here we found that in the course of CD45 processing upon stimulation with PMA or zymosan, sequential cleavage of CD45 molecules by serine-and metallo-proteases and the presenilin/γ-secretase pathway leads to the generation of ct-CD45 in phagocytes.
The reutilization of intracellular proteins for alternative functions is an emerging theme in cell biology. Release of cytoplasmic or nuclear proteins such as HMGB-1 from dying cells or by non-classical (i.e. Golgi-independent) release mechanisms has been shown to function as a "danger signal" leading to the activation of DC and consequently promote adaptive immunity. [53] [54] [55] We also observed that ct-CD45 seems to be released, but not produced, mainly upon cell death during PMA and zymosan stimulation. Yet, non-classical release mechanisms may also be involved in the release of ct-CD45. In contrast to HMGB-1, ct-CD45 acted as an inhibitory factor. One could speculate that released ct-CD45 helps to prevent exaggerated immune responses executed by T cells.
How ct-CD45 inhibits T cell proliferation remains to be determined.
However, direct binding to preactivated T cells suggests that there might be a specific receptor for ct-CD45. CD45 and in particular its intracellular part, is known to interact with a number of proteins, including various protein kinases (e.g. Lck and Fyn), cytoskeletal proteins such as fodrin and intramembrane cell surface receptors such as CD2. 13 Thus, on condition that it is expressed on the cell-surface, one of the already described binding partners for the intracellular part of CD45 could also serve as an extracellular counter-
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For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From receptor for ct-CD45 on activated T cells. Casein-kinase 2 (CK-2) is an intracellular binding partner of CD45 but has been reported to be expressed upon cell activation on the outside of cell membranes and functions as ectoprotein kinase. [56] [57] [58] We have investigated whether CK-2 is expressed outside of activated T cells, but mAb 1AD9 against CK-2 showed no extracellular surface reactivity and did not inhibit binding of ct-CD45 to T cells. Thus, CK-2 may not act as a cell surface receptor for ct-CD45 on T cells (data not shown).
Inhibition of T cell proliferation seems to be independent of the phosphatase activity of CD45 as we found it also with a phosphatase-dead fusion protein. Interestingly inhibition was not only seen upon stimulation with an Ig fusion protein covering the total intracellular part or the D1 domain but also with a D2-Ig protein. Still, the inhibitory activity of D2-Ig was weaker than D1-Ig, especially at lower concentrations. Although it is surprising that both PTP domains are able to act inhibitory these results are supported by data that the tertiary structures of D1 and D2 are very similar. 25 Remarkably, ct-CD45 was only generated in phagocytes like monocytes and granulocytes, but not in T cells, B cells or in DC. Monocytes and granulocytes are capable to produce a strong respiratory burst.
Considering that, together with our observation that ct-CD45 generation was blocked by an inhibitor of NADPH-oxidase, we can speculate that oxidative burst formation is an important factor in the generation of ct-CD45.
Phagocytes and their ability to induce an oxidative burst play a central role in the first line of defense against fungi. Yet, recent studies also support the idea that phagocytes and factors derived from these innate immune cells such as
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